Title: Naringin Alleviates Diabetic Kidney Disease through Inhibiting Oxidative Stress and Inflammatory Reaction
What Caught Our Attention: PLOS ONE had a few reasons for retracting a 2015 paper about a treatment for kidney disease due to diabetes: For one, despite what the paper claims, the authors did not obtain ethical approval to conduct the reported animal experiments. In addition, the corresponding author had no idea the paper had been submitted and published. How could a corresponding author be kept in the dark? It turns out, the journal was given an incorrect email address for him, so he didn’t receive any communications around the paper. (One author apparently used a third party editing company.) Continue reading Caught Our Notice: Forged email for corresponding author dooms diabetes paper
Here’s something we don’t see that often — authors retracting one of their articles because it included new data.
Titles:


If you’re unfamiliar with the work of Tom Spears, a reporter at the Ottawa Citizen, you have missed some 
In 2009, a university announced a prominent researcher in the field of protein crystallography had likely fabricated nearly a dozen protein structures. Nine years later, the U.S. Office of Research Integrity (ORI) has upheld the results — and announced a relatively long sanction, by the agency’s standards. 